Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma

Hodgkin lymphoma (HL) represents ~11% of all lymphoma cases. This disease occurs in young adults, but also affects people over 55 years of age. Despite the fact that >80% of all newly diagnosed patients under 60 will achieve a sustained complete response (CR), 5%–10% of HL patients are refractory...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Recio, Marta, Martinez-Serra, Jordi, Mestre, Francesc, Bento, Leyre, Gines, Jordi, Ramos, Rafael, Daumal, Jaime, López, Paloma, Sampol, Antonia, Gutierrez, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188182/
https://www.ncbi.nlm.nih.gov/pubmed/30349293
http://dx.doi.org/10.2147/OTT.S175016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188182/
https://www.ncbi.nlm.nih.gov/pubmed/30349293
http://dx.doi.org/10.2147/OTT.S175016

Ejemplares similares